...
首页> 外文期刊>Medicinal chemistry research: an international journal for rapid communications on design and mechanisms of action of biologically active agents >Multifunctional quinoxaline-hydrazone derivatives with acetylcholinesterase and monoamine oxidases inhibitory activities as potential agents against Alzheimer's disease
【24h】

Multifunctional quinoxaline-hydrazone derivatives with acetylcholinesterase and monoamine oxidases inhibitory activities as potential agents against Alzheimer's disease

机译:具有乙酰胆碱酯酶和单胺氧化酶的多官能喹喔啉 - 腙衍生物抑制活性剂免受阿尔茨海默病的潜在药剂

获取原文
获取原文并翻译 | 示例

摘要

Multitarget molecules are considered as an effective way for the treatment of AD, instead of the classic one-drug-one-target strategy because of the multifactorial nature of AD. A variety of studies indicate that several enzymes inhibitors can be useful in the treatment of AD, including acetylcholinesterase (AchE), butyrylcholinesterase (BuChE) and monoamine oxidase (MAO). Various substituted quinoxaline-hydrazone derivatives were synthesized, and their activity in vitro were investigated, including AChE/BuChE inhibitory activity and MAOA/B inhibitory activity. Based on the experimental results, compound 5l exhibited good inhibitory potency on both AchE (IC50 = 0.028 +/- 0.001 mu M) and monoamine oxidase B (IC50 = 0.046 +/- 0.002 mu M). Molecular modeling studies showed that 5l could bind to the active site of AChE and MAO-B. Taken together, these results suggested that compound 5l might be a potential multifunctional agent for the treatment of AD.
机译:由于广告的多因素,多价分子被认为是治疗广告的有效方法,而不是经典的单药 - 单目标策略。 各种研究表明,几种酶抑制剂可用于治疗AD,包括乙酰胆碱酯酶(ACHE),丁酰胆碱酯酶(BUCHE)和单胺氧化酶(MAO)。 合成各种取代的喹喔啉 - 腙衍生物,研究了它们体外的活性,包括疼痛/ Buche抑制活性和MaOA / B抑制活性。 基于实验结果,化合物5L在疼痛(IC50 = 0.028 +/-0.001μm)和单胺氧化酶B(IC50 = 0.046 +/-0.002μm)上表现出良好的抑制效力。 分子建模研究表明,5L可以与疼痛和MAO-B的活性位点结合。 总之,这些结果表明化合物5L可能是用于治疗AD的潜在多功能剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号